STERIS plc (STE) Stock Price: $210.60+3.43 (+1.66%)
At close: Jun 25, 2026, 4:00 PM ET
The closing share price for STERIS plc (STE) stock was $210.60 for Thursday, June 25, 2026, up 1.66% on the day.
Longer view (total return, dividends reinvested): past 12 months -11.5% · 3-year avg +1.0%/yr · 5-year avg +1.3%/yr
STE Price Chart
STE Key Metrics
See All MetricsLAST CLOSE PRICE
$210.60
52-WEEK RANGE
$195.14 - $269.44
BETA
0.92
% FROM 52W HIGH
-21.84%
MARKET CAP
$20.52B
DIVIDEND YIELD
1.20%
PE RATIO
trailing TTM
26.56
PE RATIO (FWD)
next-FY estimate
20.65
P/B RATIO
2.88
DEBT / EQUITY
0.29
REVENUE TTM
$5.94B
NET INCOME TTM
$782.40M
NET PROFIT MARGIN TTM
13.18%
TTM TOTAL RETURN
-11.46%
3Y TOTAL RETURN
+0.97%
5Y TOTAL RETURN
+1.32%
STE Revenue by Segment
How STE’s revenue breaks down across its reported segments in the latest reported fiscal year.
By product / business (FY 2026)
- Product$3.06B51.6%
- Services$2.88B48.4%
By geography (FY 2026)
- United States$4.33B73.0%
- Other foreign locations$1.49B25.2%
- Ireland$108.50M1.8%
STE Earnings Preview
Next Earnings Date
Aug 5, 2026
40 days away
EPS Estimate
2.52
Revenue Est.
$1.50B
Last Quarter Results
EPS
$2.83
vs Estimate
$2.85
Revenue
$1.59B
vs Estimate
$1.59B
STE Analyst Ratings
Consensus Rating
Based on 7 analysts
Average Price Target
$256.86
+22.0% upside
Low
$225.00
Current
$210.60
High
$280.00
STE Analyst Estimates
Earnings Per Share (EPS) Estimates
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Q2 2026 | $2.47 | $2.50 | $2.52 | 4 |
| Q3 2026 | $2.67 | $2.70 | $2.72 | 4 |
| Q4 2026 | $2.78 | $2.81 | $2.83 | 2 |
| Q1 2027 | $3.13 | $3.15 | $3.18 | 2 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $10.19 | $10.20 | $10.21 | 5 |
| FY 2027 | $10.90 | $11.16 | $11.25 | 6 |
Revenue Estimates
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Q2 2026 | $1.49B | $1.50B | $1.51B | 4 |
| Q3 2026 | $1.55B | $1.56B | $1.57B | 4 |
| Q4 2026 | $1.60B | $1.61B | $1.62B | 3 |
| Q1 2027 | $1.69B | $1.70B | $1.71B | 3 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $5.92B | $5.94B | $5.95B | 6 |
| FY 2027 | $6.35B | $6.36B | $6.38B | 6 |
Source: FMP Analyst Consensus Estimates. Forward P/E uses the next-fiscal-year consensus EPS estimate (the same value shown in the Key Metrics strip).
Related Stocks
HealthcareSTE Competitors' Key Metrics
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1STE | $20.52B | $210.60 | +1.66% | -11.46% | +1.32% | +13.60% | — |
| 2INCY | $21.48B | $107.53 | -0.86% | +59.24% | +4.37% | +3.40% | vs STE |
| 3LH | $21.83B | $266.20 | +0.38% | +3.99% | +4.07% | +9.67% | vs STE |
| 4VTRS | $18.71B | $16.07 | +0.88% | +87.86% | +6.35% | -7.50% | vs STE |
| 5BNTX | $22.76B | $90.00 | -0.23% | -14.13% | -16.89% | N/A | vs STE |
| 6DGX | $22.83B | $206.24 | +1.54% | +17.53% | +11.90% | +12.28% | vs STE |
STE Charts
Valuation Charts
Performance Charts
CAGR Charts
Financial Statement Charts
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- Capital Expenditure
- Acquisitions
- Share Buybacks
- Stock-Based Compensation
- Total Assets
- Total Equity
- Cash & Equivalents
- Accounts Receivable
- Inventory
- PP&E
- Goodwill
- Accounts Payable
- Retained Earnings
- Total Debt
- Long-Term Debt
- Short-Term Debt
About STERIS plc
STERIS plc provides infection prevention products and services worldwide. It operates in three segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in procedure rooms, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument, devices, and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. The AST segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of contract sterilization and laboratory facilities, as well as integrated sterilization equipment and control systems to medical device manufacturers and research institutions. The Life Sciences segment designs, manufactures, and sells consumable products, such as pharmaceutical detergents, cleanroom disinfectants and sterilants, pharmaceutical grade and research sterilizers and washers, sterility assurance and maintenance products, vaporized hydrogen peroxide room decontamination systems and sterilizers, and high purity water and pure steam generators. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. It serves its products and services to hospitals, other healthcare providers, and pharmaceutical manufacturers. The company was founded in 1985 and is headquartered in Mentor, Ohio.
- Sector
- Healthcare
- Industry
- Medical - Equipment & Services
- CEO
- Daniel A. Carestio